Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Treatt warns on profits, shares dive

(Sharecast News) - Shares in Treatt plunged on Thursday, after the extracts and ingredients specialist warned on profits following a tough first half. Updating on trading, the group - which supplies the beverage, flavour and fragrance industries - said it had been hit by lower demand, weaker consumer confidence and higher costs.

In particular, "sustained" high citrus prices affected demand in its heritage unit, while softer consumer confidence in the US weighed heavily on the North American beverage market.

As a result, first half revenues fell to £64.2m from £72.1m, while profits before tax and exceptionals slid to £3.6m from £7.6m, prompting Treatt to cut its full-year guidance.

It now expects revenues to come in between £146m and £153m, and pre-tax profits before exceptional items between £16m and £18m.

In the year to 30 September 2024, Treat posted pre-tax profits before exceptional items of £19.1m on revenues of £153.1m.

As at 0945 BST, shares in Treatt had lost more than a quarter of their value, down 26% at 237p.

David Shannon, chief executive, said: "Treatt made meaningful strategic progression in the first half.

"While we are disappointed by the impact on profitability of predominantly short-term trading challenges, we are encouraged by our robust order book and sales pipeline, and expect to realise the benefit of self-help measures within the second half.

"We are confident in the medium-term outlook."

Treatt is due to post results for the six months to 31 March on 13 May.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.